Intrexon Corp  

(Public, NYSE:XON)   Watch this stock  
Find more results for XON
+0.07 (0.28%)
After Hours: 25.36 0.00 (0.00%)
Jun 23, 6:38PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 24.78 - 25.80
52 week 18.41 - 32.90
Open 25.18
Vol / Avg. 1.12M/1.25M
Mkt cap 3.20B
P/E     -
Div/yield     -
EPS -1.30
Shares 119.61M
Beta 1.53
Inst. own 87%
Aug 7, 2017
Q2 2017 Intrexon Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 28, 2017
Intrexon Corp Annual Shareholders Meeting - 9:00AM EDT - Add to calendar
Jun 20, 2017
Intrexon Corp at JMP Securities Life Science Conference - Webcast
Jun 19, 2017
Intrexon Corp at Biotechnology Industry Organization (BIO) International Convention
Jun 14, 2017
Intrexon Corp at Goldman Sachs Global Healthcare Conference - Webcast
Jun 9, 2017
Intrexon Corp Annual Shareholders Meeting (Estimated)
May 24, 2017
Intrexon Corp at B. Riley Investor Conference
May 16, 2017
Intrexon Corp at Bank of America Merrill Lynch Healthcare Conference - Webcast
May 16, 2017
Intrexon Corp at Bank of America Merrill Lynch Healthcare Conference (Panel)
May 13, 2017
Intrexon Corp at American Society of Gene & Cell Therapy Meeting
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '17) 2016
Net profit margin -51.04% -88.60%
Operating margin -58.39% -65.56%
EBITD margin - -52.69%
Return on average assets -11.80% -17.52%
Return on average equity -23.13% -29.76%
Employees 832 -
CDP Score - -


1750 Kraft Dr Ste 1400
BLACKSBURG, VA 24060-6147
United States - Map
+1-301-5569809 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company's domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company's synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company's technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Officers and directors

Randal J. Kirk Chairman of the Board, Chief Executive Officer
Age: 63
Bio & Compensation  - Reuters
Thomas D. Reed Ph.D. Founder, Chief Science Officer
Age: 51
Bio & Compensation  - Reuters
Rick L. Sterling CPA Chief Financial Officer
Age: 53
Bio & Compensation  - Reuters
Andrew J. Last Ph.D. Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
Joel Liffmann Senior Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
Jack Anthony Bobo Senior Vice President, Chief Communications Officer
Age: 51
Bio & Compensation  - Reuters
Ena Chan Cratsenburg Senior Vice President - Consumer Sector
Age: 48
Bio & Compensation  - Reuters
Nir Nimrodi Senior Vice President - Corporate Development
Age: 48
Bio & Compensation  - Reuters
Jeffrey T. Perez Senior Vice President — Intellectual Property Affairs
Age: 45
Bio & Compensation  - Reuters
Christopher Basta Vice President - Investor Relations
Bio & Compensation  - Reuters